Published in EClinicalMedicine, a journal of The Lancet, the review included 131 studies from 26 countries published between Jan. 24 and May 14. Together, the studies include 7,780 pediatric patients. The majority of the studies were from China, but the largest study that was included was a case series of 2,572 patients reported by the CDC.
Five study findings:
1. About 3.3 percent of the patients were admitted to intensive care units.
2. Seven patients (0.09 percent) died.
3. About 5.6 percent suffered from co-infections, such as influenza, in addition to COVID-19.
4. Eleven children (0.14 percent) met the criteria for pediatric multisystem inflammatory syndrome.
5. Nineteen percent of the patients were asymptomatic.
More articles on patient safety & outcomes:
10% drop in ER volume significantly cuts patient death rates, study finds
Obesity common among kids hospitalized with COVID-19, study finds
76% of COVID-19 patients treated with convalescent plasma improve, small study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
